Our Technology
Drug Delivery to the Brain is Challenging Due to the BBB’s Selective Nature, Limiting the Access and Effectiveness of Cancer Therapies in the Brain
The blood-brain barrier is a natural defense that protects the brain from toxins and infections but has also stood as one of the greatest challenges in the treatment of glioblastoma and other CNS cancers, blocking many promising therapies from reaching the tumor. At CNS Pharmaceuticals, our technology is designed to potentially overcome this obstacle, enabling therapeutics to enter the brain and attack tumors.
Highly Selective, Semi-Permeable Barrier that Separates the Circulating Blood from the Brain
Key Functions
- Protection:
- Blocks toxins, pathogens and potentially harmful molecules from entering the brain by transporters that bind to these substances and deliver them back to the bloodstream
- Selective Permeability:
- Allows essential nutrients like glucose and amino acids to pass through while restricting larger or harmful molecules
- Maintaining Homeostasis:
- Ensures a controlled environment for proper neuronal function
TPI-287
TPI 287 is a small molecule belonging to the taxane diterpenoid (taxoid) family, specifically to the abeotaxane class. Historically, taxanes have not been used in neuro-oncology applications because as a class they lack the ability to penetrate the BBB.
TPI 287 is not a substrate for any of the important BBB efflux pumps and appears to concentrate in the brain, which has been demonstrated by several preclinical studies.